Abstract

PPAR- α/γ AGONISTS: A NEWER APPROACH TO DIABETIC DYSLIPIDEMIA

Mital Bhadania*, Falguni Majmudar

Abstract

Diabetes mellitus is a worldwide prevalent chronic disease with a significant disease burden. Every fourth diabetic in the world is an Indian. Incidence of dyslipidemia among people suffering from diabetes is shooting up each year around the globe. Atherogenic diabetic dyslipidemia (ADD) is an important cardio vascular disease risk factor. Statins are irrefutably the first line of drugs for dyslipidemia management in patients with residual CV risk while on a statin, peroxisome proliferator activated receptor (PPAR)-α/γ agonists have been found to be of substantial benefit. Reduction ADD improved glycemic control, efficacy at par with fibrates, and an acceptable safety profile from the grounds on which this group of PPAR-α/γ agonists, with their novel mechanism, holds a promising future in the management of diabetic dyslipidemia. A novel target to control this disorder has agonistic activity on PPAR-α/γ receptors simultaneously. PPAR-α has lipid lowering agent while PPAR-γ is lowering in blood glucose and effective insulin sensitizers. Saroglitazar developed as new chemical entity discovered and developed PPAR-α/γ agonist. Saroglitazar, a dual PPAR-α/γ agonist is a potential therapeutic option for the management of diabetic dyslipidemia. It has dual benefit of significant improvement in glycemic parameters (glycated hemoglobin and fasting blood glucose) and significantaly improvement in dyslipidemia (TGs, apolipoprotein β, non-HDL-C). Saroglitazar is a novel nonthiazolidinediones and nonfibric acid derivative designed to act as dual regulator of lipids and glucose metabolism by activating PPAR.

Keywords: Diabetes mellitus, Diabetes Dyslipidemia, Peroxisome Proliferator Activated Receptor, Saroglitazar, PPAR-?/? agonist.